Sector Snap: Drug-Coated Stent Makers
|
|
NEW YORK (Associated Press) - The share of Boston Scientific Corp. gained traction Tuesday against rival stent from Abbott Laboratories, study data showed its drug-coating Taxus stents have been effective in reducing the need for prosecute heart procedures, compared with Bare Metal stent. In return, Abbott reported data, which showed its Xience V stent reduces heart problems compared with Taxus, but the results were not statistically significant. Xience V is not yet the Food and Drug Administration. The study results were presented at the American College of Cardiology Conference in Chicago Monday. Natick, Massachusetts-based Boston Scientific and North Chicago, Ill.-based Abbott are among many others saw the medical device, a turnover that companies of stents coated with drugs because of security concerns blood clots were two years ago. Since then, the company has continued to study the safety devices and efficiency. The stents are tiny wire mesh tubes that prop open arteries after they have been surgically removed plaques fat. Drug coatings used to prevent the growth of scar tissue on the wires, but the data beat two years, another coating May, patients at high risk of blood clots. Boston Scientific reports the results of a study of 2458 patients who have shown, participants who had the drug covered stents revascularization lower prices, including cardiac bypass. The share of the company rose 47 cents or 3.7 percent to 13.34 dollars in trade noon. Abbott said with a stent patients had a lower rate of myocardial infarction and death compared with Boston Scientific, the product, even if the results were not statistically significant. Abbott share fell to 33 cents to 54.82 dollars. Still, Wachovia Capital Markets Larry Biegelsen expects Abbott’s stent on the market. He said that the company is probably advertise its efforts focused on the entire body of clinical evidence surrounding Xience. He said, Medtronic Inc. ’s Endeavor stent was also some scepticism, after several cases of blood clots, but since then, the attention moves on the general safety of stents. Shares of Minneapolis based Medtronic Inc. rose 31 cents to 48.68 dollars. The share of Johnson & Johnson, the Cypher stent, added 58 cents to 65.45 dollars. Also on the agenda of the conference, Palo Alto, California-based CV Therapeutics Inc. presented his study on data from chronic angina drug Ranexa, how it moves, for other brands. Its stock rose 29 cents or 4 percent to 7.42 dollars. Whitehouse Station, New Jersey-based Merck & Co. Gained 40 cents to $ 38.35 Monday after jumping on negative messages on the cholesterol drug Vytorin and several other drugs. |